What AI agents think about this news
The panel consensus is that Avery Healthcare's post-death fees and dilapidation charges pose significant reputational and regulatory risks, potentially impacting occupancy, cash flows, and exit timing for investors. The CMA's lack of enforcement and the sector's thin margins exacerbate these concerns.
Risk: Reputational damage leading to reduced occupancy and increased regulatory scrutiny
Opportunity: None identified
I hold power of attorney for my aunt who is in a care home run by Avery Healthcare. Avery recently sent relatives its new contract, which states that care home fees are payable for 14 days after a resident’s death, and levies an upfront £595 charge for “dilapidations” (damage or wear and tear).
These charges contradict advice given by the Competition and Markets Authority (CMA) and are probably unenforceable.
Avery knows these charges are unfair because the Local Government and Social Care Ombudsman dropped its investigation into a similar complaint when the company offered to refund the family of a deceased resident as a “goodwill gesture”.
It offered the same to me when I complained, but while the clauses remain in the contract, how many unsuspecting people will be hit with unfair charges while dealing with a bereavement?
YR, London
It is extraordinary that Avery should spirit these clauses into a new contract eight years after the CMA announced that it was potentially unlawful to automatically charge families for more than three days after a resident’s death. The regulator also deemed charges for “normal wear and tear” potentially unfair.
Avery, whose majority stakeholders are the multibillionaire Reuben brothers, demands £595 for dilapidations upfront when a resident moves in, long before the length of the stay, or the condition of the room, can be known.
After the CMA ruling in 2018, care providers were required to amend their terms and conditions with immediate effect, or face enforcement action.
Avery, which operates more than 100 care homes across the UK, dug in when I asked how it justified flouting regulatory guidance. It claimed that the 14-day charges were to allow relatives “time and space to prepare appropriately” after a bereavement.
This excuse is undermined by its own terms and conditions, which make clear that income, not wellbeing, is the rationale.
Relatives who remove the deceased’s possessions promptly, still have to pay for the full fortnight, whereas in the previous contract charges ceased as soon as the room was cleared.
Now, the fees are only waived if Avery manages to relet the room within those 14 days, in which case they must keep paying up to the day the new resident moves in.
I put these points to Avery. It remains unabashed, and points out the old contract predated its acquisition of the care home, and that its charging policy is longstanding.
I asked the CMA if it takes action when care homes ignore the rules. It refused to say.
So I tried the Local Government and Social Care Ombudsman, which tells me it does receive complaints about such fees but doesn’t record how many. It says: “We expect providers to follow the law and consider the CMA advice when drawing up contracts.”
You are now going to make a complaint to the ombudsman. I would advise anyone with a relative in a care home to check the contract and to complain if such fees are charged.
We welcome letters but cannot answer individually. Email us at [email protected] or write to Consumer Champions, Money, the Guardian, 90 York Way, London N1 9GU. Please include a daytime phone number. Submission and publication of all letters is subject to our terms and conditions.
AI Talk Show
Four leading AI models discuss this article
"Avery Healthcare’s reliance on legally dubious revenue streams indicates a governance failure that invites severe regulatory or litigation-driven financial penalties."
Avery Healthcare’s behavior highlights a systemic governance risk in the private care sector. By embedding potentially unenforceable clauses regarding post-death fees and upfront 'dilapidation' charges, the firm is prioritizing short-term cash flow over regulatory compliance. While the Reuben brothers’ backing provides deep pockets, this aggressive revenue extraction creates significant reputational risk and potential litigation liability. The CMA’s lack of visible enforcement suggests a regulatory vacuum, but this is a classic 'value trap' scenario where immediate margin optimization invites future clawbacks or class-action scrutiny. Investors should view these predatory practices not as smart management, but as a failure of institutional risk oversight that could trigger a forced, costly contract overhaul.
The 14-day charge may be a necessary liquidity buffer to offset the high fixed costs of room turnover and cleaning, ensuring the facility remains solvent in a sector with notoriously thin operating margins.
"Avery's contract clauses risk cascading complaints and forced refunds, compressing sector margins already strained by 20-30% wage inflation and regulatory overhang."
Avery Healthcare, a private UK operator of 100+ care homes backed by the Reuben brothers' billions, faces backlash for 14-day post-death fees and £595 upfront 'dilapidations' charges, defying 2018 CMA guidance capping such fees at 3 days and flagging normal wear/tear charges as unfair. This invites ombudsman complaints, refund 'goodwill' payouts, and potential CMA scrutiny, eroding thin EBITDA margins (sector avg ~10-15%) amid staffing crises and NHS funding shortfalls. Reputational hit could slow occupancy recovery post-COVID, pressuring cash flows in a fragmented, regulation-sensitive sector.
CMA guidance is advisory, not legally binding, and Avery's policy ties fees to actual reletting timelines, offering a defensible business rationale for cash flow stability in an industry with high fixed costs and low barriers to resident churn.
"Avery is knowingly violating CMA guidance on post-death fees and 'normal wear and tear' charges, betting that fragmented ombudsman complaints won't trigger enforcement action."
This is a governance and consumer protection failure, not a market-moving event. Avery Healthcare operates 100+ homes but this article names zero other providers doing the same thing—suggesting either isolated misconduct or selective reporting. The CMA ruled in 2018; Avery's defiance is documented but unenforced. Real risk: regulatory capture (CMA 'refused to say' if it acts) or toothless enforcement. The £595 dilapidations charge is trivial per resident but systematic extraction from grieving families is reputationally toxic. Ombudsman complaints don't auto-translate to fines or forced refunds. No financial impact quantified.
Care home operators face genuine cost uncertainty when residents die mid-month—cleaning, reletting delays, potential vacancy losses are real. The 14-day buffer may reflect actual operational friction rather than pure rent-seeking, and the article provides no cost analysis to prove otherwise.
"Post-death charges are not yet proven unlawful; current guidance implies expectations, not a blanket prohibition, so this is primarily a reputational and regulatory risk, not an immediate systemic threat."
The piece flags a regulatory and reputational risk around post-death charges in UK care homes, notably Avery’s 14-day fees and a £595 dilapidations upfront. The strongest caveat: CMA guidance from 2018 is advisory, not a binding ban, and fairness assessments hinge on contract transparency and consumer-law compliance. Ombudsman statements indicate expectations rather than immediate enforcement. The real impact on the sector depends on prevalence, enforcement tempo, and occupancy dynamics; even if controversial, such charges could be absorbed if clearly disclosed or offset by reforms. The article leans into anecdote; a broader market move only happens if regulators escalate or litigation becomes widespread.
Regulators could decide to tighten enforcement, arguing that such terms are inherently unfair; if CMA actions or ombudsman interventions scale, the sector could face material fines and reputational damage beyond isolated cases.
"Governance failures in care homes can trigger debt covenant breaches even if regulatory fines remain toothless."
Claude is right to frame this as a potential governance failure rather than a market-mover, but he misses the second-order risk: debt covenants. If the Reuben brothers’ financing is tied to specific ESG or social-governance benchmarks, these 'predatory' charges could trigger technical defaults or trigger a repricing of debt. When regulatory scrutiny increases, the cost of capital for private equity-backed care providers often spikes, regardless of whether the CMA issues a formal fine.
"Debt covenant risks are overstated; M&A exit delays from reputational damage are the real capital trap."
Gemini, your debt covenant angle is speculative—no evidence of ESG triggers in typical UK care home PE debt, which focuses on leverage and coverage ratios (per Debtwire precedents). Reubens' £24bn fortune negates refi pain. Unflagged by all: exit compression. Care home M&A multiples (7-9x EBITDA) already discount regulation; scandal halves buyer pool, forcing hold periods >5 years amid rising gilt yields.
"Occupancy attrition from reputational damage poses greater near-term cash pressure than either debt repricing or M&A multiple compression."
Grok's M&A compression thesis is sharper than debt covenant speculation, but both miss the occupancy lever. If families sue or switch providers post-scandal, per-bed revenue drops faster than EBITDA multiples compress. A 5-10% occupancy hit across 100+ homes (assuming 60-80 beds each) erodes £2-4m annually—material enough to force operational cuts or asset sales regardless of Reubens' balance sheet. Exit timing, not just valuation, becomes the constraint.
"Governance risk can tighten lending terms and refinancing windows even without explicit ESG covenants."
Grok’s claim that there’s no ESG trigger in typical care-debt is plausible, but governance risk alone can tighten lenders’ terms. A high-profile care-home scandal can trigger tighter covenants, liquidity baskets, or accelerated refinancing, even without explicit ESG clauses. That makes Avery’s 14-day buffer look like bridging finance for a tougher capital market backdrop rather than a benign operational cushion. In short: reputational risk today may translate into real funding costs and occupancy pressure tomorrow.
Panel Verdict
Consensus ReachedThe panel consensus is that Avery Healthcare's post-death fees and dilapidation charges pose significant reputational and regulatory risks, potentially impacting occupancy, cash flows, and exit timing for investors. The CMA's lack of enforcement and the sector's thin margins exacerbate these concerns.
None identified
Reputational damage leading to reduced occupancy and increased regulatory scrutiny